Osteoporosis associated with rheumatoid arthritis: Pathogenesis and management☆

https://doi.org/10.1016/0049-0172(91)90021-QGet rights and content

Abstract

Rheumatoid arthritis is associated with both localized and generalized osteoporosis. Localized osteoporosis can be considered to be caused by local disease mechanisms, including the generation of factors from activation of the cytokine pathway. The etiology of generalized osteoporosis has been difficult to elucidate, particularly because of the lack of sensitive techniques to measure bone mineral density. The introduction of single- and dual-photon absorptiometry and quantitative computed tomography has allowed more accurate assessment of bone mineral density. In general, bone mineral density loss at appendicular sites does not correlate well with axial bone density loss. Corticosteroid treatment exaggerates the development of osteoporosis in up to 40% of patients with rheumatoid arthritis. Sex hormone status, physical activity, disease duration, and functional class are all significant predictors for the development of osteoporosis. Current therapy for prevention and treatment is based largely on theoretical considerations. Physical activity should be encouraged once acute joint inflammation has settled. Postmenopausal women and amenorrheic premenopausal women will benefit from cyclical estrogen replacement. Patients with low serum 1,25-dihydroxy vitamin D3 levels, and males with low serum testosterone levels, are candidates for replacement therapy with the appropriate hormones. In patients who are receiving corticosteroids the dose should be limited, and oral calcium supplements are of benefit. The use of the newer corticosteroid deflazacort, and disease-modifying immunosuppressive drugs, are discussed. Other therapeutic options which should be considered, although published trials are scarce, are calcitonin and the diphosphonates. Further studies are awaited concerning the optimum prevention and treatment of osteoporosis associated with rheumatoid arthritis. For the present, management should be based on theoretical considerations. The introduction of dual-energy X-ray absorptiometry for measuring bone mineral density represents a significant improvement over the older techniques, and will assist in future clinical trials. Inhibitors of the cytokine pathway, or the products stemming from activation of this pathway, need to be evaluated in the treatment of osteoporosis associated with rheumatoid arthritis.

References (153)

  • J Aubia et al.

    Bone histology in renal transplant patients receiving cyclosporin

    Lancet

    (1988)
  • RY Calne

    Cyclosporin in cadaveric renal transplantation: 5-year follow-up of a multicentre trial

    Lancet

    (1987)
  • F.C. Arnett et al.

    The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis

    Arthritis Rheum

    (1988)
  • E.D. Harris

    Rheumatoid arthritis. Pathophysiology and implications for therapy

    N Engl J Med

    (1990)
  • P.E. Lipsky

    The control of antibody production by immunomodulatory molecules

    Arthritis Rheum

    (1989)
  • C.A. Dinarello et al.

    Lymphokines

    N Engl J Med

    (1987)
  • S Shimizu et al.

    Quantitative histologic studies on the pathogenesis of periarticular osteoporosis in rheumatoid arthritis

    Arthritis Rheum

    (1985)
  • T Takashima et al.

    Inflammatory cell changes in Haversian canals

    J Bone Joint Surg (Br)

    (1989)
  • D.R. Robinson et al.

    Prostaglandin-stimulated bone resorption by rheumatoid synovia

    J Clin Invest

    (1975)
  • F.E. Dewhirst et al.

    Purification and partial sequence of human osteoclast-activating factor: identity with interleukin 1β

    J Immunol

    (1985)
  • S.B. Mizel et al.

    Stimulation of rheumatoid synovial cell collagenase and prostaglandin production by partially purified lymphocyte-activating factor (interleukin 1)

  • S.C. Gilman et al.

    Interleukin-1 activates phospholipase A2 in human synovial cells

    Arthritis Rheum

    (1988)
  • V Shen et al.

    Characterization and hormonal modulation of IL-1 binding in neonatal mouse osteoblastlike cells

    J Bone Miner Res

    (1990)
  • T Saxne et al.

    Detection of tumor necrosis factor a but not tumor necrosis factor β in rheumatoid arthritis synovial fluid and serum

    Arthritis Rheum

    (1988)
  • N Miyasaka et al.

    Augmented interleukin-1 production and HLA-DR expression in the synovium of rheumatoid arthritis patients

    Arthritis Rheum

    (1988)
  • M Degre et al.

    Immune interferon in serum and synovial fluid in rheumatoid arthritis and related disorders

    Ann Rheum Dis

    (1983)
  • M Gowen et al.

    Actions of recombinant human γ-interferon and tumor necrosis factor a on the proliferation and osteoblastic characteristics of human trabecular bone cells in vitro

    Arthritis Rheum

    (1988)
  • F.A. Houssiau et al.

    Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides

    Arthritis Rheum

    (1988)
  • J.A. Wilkins et al.

    The demonstration of an interleukin-2 like activity in the syno vial fluids of rheumatoid arthritis patients

    J Rheumato

    (1983)
  • AM Nouri et al.

    Cytokines and the chronic inflammation of rheumatic disease. II. The presence of interleukin-2 in synovial fluids

    Clin Exp Immunol

    (1984)
  • RM McKenna et al.

    Interleukin 2 production and responsiveness in active and inactive rheumatoid arthritis

    J Rheumatol

    (1986)
  • SJ Weiss

    Tissue destruction by neutrophils

    N Engl J Med

    (1989)
  • DG Malone et al.

    Mast cell numbers and histamine levels in synovial fluids from patients with diverse arthritides

    Arthritis Rheum

    (1986)
  • B Gruber et al.

    Characterization and functional studies of rheumatoid synovial mast cells

    Arthritis Rheum

    (1986)
  • P.E. Korenblat et al.

    Systemic mastocytosis

    Arch Intern Med

    (1984)
  • S Havelka et al.

    Bone indexes and cortical thickness in assessing osteoporosis in rheumatic patients

    Scand J Rheumatol

    (1973)
  • AC Kennedy et al.

    Generalized and localized bone loss in patients with rheumatoid arthritis

    Scand J Rheumatol

    (1975)
  • T.J. Hahn et al.

    Effect of chronic corticosteroid administration on diaphyseal and metaphyseal bone mass

    J Clin Endocrinol Metab

    (1974)
  • A.O. Bjelle et al.

    Osteoporosis in rheumatoid arthritis

    Calc Tissue Res

    (1970)
  • V.J. Hajiroussou et al.

    Prolonged low-dose corticosteroid therapy and osteoporosis in rheumatoid arthritis

    Ann Rheum Dis

    (1984)
  • H.E. Meema et al.

    Cortical bone mineral density versus cortical thickness in the diagnosis of osteoporosis: A roentgenologic-densitometric study

    J Am Geriatr Soc

    (1969)
  • P Schneider et al.

    The relationship of peripheral to axial bone density

    Bone Miner

    (1988)
  • R.B. Mazess et al.

    Radial and spinal bone mineral density in a patient population

    Arthritis Rheum

    (1988)
  • S.M. Ott et al.

    Comparisons among methods of measuring bone mass and relationship to severity of vertebral fractures in osteoporosis

    J Clin Endocrinol Metab

    (1988)
  • R.B. Mazess et al.

    Bone density of the radius, spine, and proximal femur in osteoporosis

    J Bone Miner Res

    (1988)
  • L Nilas et al.

    Long-term precision of dual photon absorptiometry in the lumbar spine in clinical settings

    Bone Miner

    (1988)
  • S.M. Ott et al.

    Ability of four different techniques of measuring bone mass to diagnose vertebral fractures in postmenopausal women

    J Bone Miner Res

    (1987)
  • A.F. Heuck et al.

    Mild versus definite osteoporosis: Comparison of bone densitometry techniques using different statistical models

    J Bone Miner Res

    (1989)
  • N.A. Pocock et al.

    Limitations of forearm bone densitometry as an index of vertebral or femoral neck osteopenia

    J Bone Miner Res

    (1986)
  • P.D. Ross et al.

    Detection of prefracture spinal osteoporosis using bone mineral absorptiometry

    J Bone Miner Res

    (1988)

    • Cited by (93)

    • 1,25-dihydroxyvitamin D<inf>3</inf> inhibits directly human osteoclastogenesis by down-regulation of the c-Fms and RANK expression

      2013, Joint Bone Spine
      Citation Excerpt :

      Contrary to these findings, several reports have demonstrated that pharmacologic doses of active vitamin D3 suppress bone resorption in animal models of excessive bone resorption [11,12]. Also in the clinical field, vitamin D supplementation is usually prescribed for patients with RA to prevent corticosteroid-induced osteoporosis [13]. Previous reports have shown that vitamin D deprivation greatly enlarged the pool of osteoclasts in growing pigs, and the pool of osteoclast progenitors in the bone marrow of ovarectomized mice was decreased by treatment with vitamin D, suggesting that vitamin D inhibited bone resorption by directly affecting the osteoclast progenitors [14,15].

    • Co-morbidities in established rheumatoid arthritis

      2011, Best Practice and Research: Clinical Rheumatology
      Citation Excerpt :

      Periarticular osteoporosis and osteopenia occur in RA, but generalised bone loss is also common, likely due to a shared mechanism via cytokine-induced osteoclast activation and osteoblast inhibition leading to bone resorption ([29], reviewed in [30,31]). The presence of increased rates of fractures in RA and the associated osteoporosis risk factors have been known for many years [32,33]. Part of this is due to reduced peripheral bone density in RA patients, which is related both to age and to steroid therapy as well as disease duration [34], and markers of RA severity including positive rheumatoid factor [35] and radiographic damage [36].

    • Bone Damage in rheumatoid arthritis: Mechanistic insights and approaches to prevention

      2010, Rheumatic Disease Clinics of North America

    • Osteocyte morphology in human tibiae of different bone pathologies with different bone mineral density - Is there a role for mechanosensing?

      2009, Bone
      Citation Excerpt :

      Therefore our results cannot be easily compared. Rheumatoid arthritis causes localized and generalized osteoporosis, and the use of corticosteroids exaggerates the development of osteoporosis in 40% of the patients with rheumatoid arthritis [44]. Therefore, the bone of the osteopenic patient in our study is an excellent representation of bone that is characterized by low BMD.

    • Osteoporosis

      2007, Rheumatic Disease Clinics of North America
      Citation Excerpt :

      Some examples of systemic inflammatory diseases associated with osteoporosis include inflammatory bowel disease, rheumatoid arthritis, and systemic lupus erythematosus [37,61]. Osteoporosis may also result from therapeutic interventions, such as with methotrexate drug therapy (decreased osteoblast function), heparin (increased osteoclast activity at doses higher than 15,000 units in 24 hours), glucocorticoids at or higher than 7.5 mg/day, or the use of anticonvulsants (which effect vitamin D metabolism and calcium absorption) [45,48,93–95,98,103–105]. Other diseases commonly associated with an increased incidence of osteoporosis include diabetes mellitus, chronic obstructive pulmonary disease, and alcoholism [85–89].

    • Rheumatoid Arthritis and other Inflammatory Joint Pathologies

      2006, Dynamics of Bone and Cartilage Metabolism: Principles and Clinical Applications
    View all citing articles on Scopus
    ☆

    Supported in part by Rorer Pharmaceutical, Ft Washington, PA.

    1

    From the Division of Endocrinology and Metabolism, Albert Einstein Medical Center, and the Department of Medicine, Temple University School of Medicine, Philadelphia, PA.

    View full text
    Copyright © 1991 Published by Elsevier Inc.